U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    33,681.18
    +1,265.39 (+3.90%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Alcobra (ADHD) in Focus: Stock Surges 24.5% - Tale of the Tape

Alcobra Ltd. (ADHD) was a big mover last session, as the company saw its shares rise roughly 24.5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 60.3% in the past one-month time frame.

The company has seen no estimate revisions in the past 30 days and the Zacks Consensus Estimate has also remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
 
Alcobra currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biotechnology stock is IGI, Laboratories, Inc. (IG), sporting a Zacks Rank #1(Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ALCOBRA LTD (ADHD): Free Stock Analysis Report
 
IGI LABORATORYS (IG): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research